Скрининг

There are no established screening guidelines for the general population for chronic kidney disease (CKD); population-wide screening for CKD is controversial.[77][78][79]

Early identification of CKD in people at risk is likely to be beneficial if it is combined with risk stratification and treatment to delay progression and reduce cardiovascular risk.[77]​​

Consensus recommendations for CKD screening and risk stratification of people considered to be at high risk have been published (subsequent to a Kidney Disease: Improving Global Outcomes [KDIGO] controversies conference).[77]

  • Screening is recommended in people with hypertension, diabetes, or cardiovascular disease.

  • Screening should be considered for people with other risk factors (e.g., older age, high-risk race/ethnicity, systemic diseases that impact kidneys, family history of kidney disease, genetic risk factors, poor access to health care or low socio-economic status, high-risk occupations and environmental exposures, prior acute kidney injury, pre-eclampsia, exposure to nephrotoxins, and obesity).

  • Decisions about starting and frequency of CKD screening should be individualised based on kidney and cardiovascular risk profiles and individual preferences.

  • Screening should include estimated glomerular filtration rate (eGFR; creatinine and cystatin C, if available) and measurement of albuminuria (urine albumin to creatinine ratio).

The American Diabetes Association recommends assessing urinary albumin and eGFR at least annually in people with type 1 diabetes of ≥5 years and all people with type 2 diabetes regardless of treatment.[80]

​The UK National Institute for Health and Care Excellence (NICE) recommends annual monitoring for patients taking drugs that can adversely affect kidney function (e.g., calcineurin inhibitors, lithium, chronic use of non-steroidal anti-inflammatory drugs [NSAIDs]).[54]

Использование этого контента попадает под действие нашего заявления об отказе от ответственности